Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults : the C4R Study
© 2024. The Author(s)..
This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-August 2022 using Luminex-based microsphere immunoassays. Of 6245 participants, mean age was 73 years (range, 21-100), 58% were female, and 76% were non-Hispanic White. Nearly 52% of participants received the BNT162b2 vaccine and 48% received the mRNA-1273 vaccine. Lower anti-S1 antibody levels are associated with age of 65 years or older, male sex, higher body mass index, smoking, diabetes, COPD and receipt of BNT16b2 vaccine (vs mRNA-1273). Participants with a prior infection, particularly those with a history of hospitalized illness, have higher anti-S1 antibody levels. These results suggest that adults with certain socio-demographic and clinical characteristics may have less robust antibody responses to COVID-19 vaccination and could be prioritized for more frequent re-vaccination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature communications - 15(2024), 1 vom: 19. Feb., Seite 1492 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV Vaccine mRNA-1273 |
|---|
| Anmerkungen: |
Date Completed 21.02.2024 Date Revised 24.02.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-024-45468-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368640957 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368640957 | ||
| 003 | DE-627 | ||
| 005 | 20240229150136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240220s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-024-45468-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1304.xml |
| 035 | |a (DE-627)NLM368640957 | ||
| 035 | |a (NLM)38374032 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, John S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults |b the C4R Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.02.2024 | ||
| 500 | |a Date Revised 24.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-August 2022 using Luminex-based microsphere immunoassays. Of 6245 participants, mean age was 73 years (range, 21-100), 58% were female, and 76% were non-Hispanic White. Nearly 52% of participants received the BNT162b2 vaccine and 48% received the mRNA-1273 vaccine. Lower anti-S1 antibody levels are associated with age of 65 years or older, male sex, higher body mass index, smoking, diabetes, COPD and receipt of BNT16b2 vaccine (vs mRNA-1273). Participants with a prior infection, particularly those with a history of hospitalized illness, have higher anti-S1 antibody levels. These results suggest that adults with certain socio-demographic and clinical characteristics may have less robust antibody responses to COVID-19 vaccination and could be prioritized for more frequent re-vaccination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Sun, Yifei |e verfasserin |4 aut | |
| 700 | 1 | |a Balte, Pallavi |e verfasserin |4 aut | |
| 700 | 1 | |a Cushman, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Boyle, Rebekah |e verfasserin |4 aut | |
| 700 | 1 | |a Tracy, Russell P |e verfasserin |4 aut | |
| 700 | 1 | |a Styer, Linda M |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, Taison D |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Michaela R |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Norrina B |e verfasserin |4 aut | |
| 700 | 1 | |a Schreiner, Pamela J |e verfasserin |4 aut | |
| 700 | 1 | |a Bowler, Russell P |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, David A |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Joyce S |e verfasserin |4 aut | |
| 700 | 1 | |a Xanthakis, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Doyle, Margaret F |e verfasserin |4 aut | |
| 700 | 1 | |a Regan, Elizabeth A |e verfasserin |4 aut | |
| 700 | 1 | |a Make, Barry J |e verfasserin |4 aut | |
| 700 | 1 | |a Kanaya, Alka M |e verfasserin |4 aut | |
| 700 | 1 | |a Wenzel, Sally E |e verfasserin |4 aut | |
| 700 | 1 | |a Coresh, Josef |e verfasserin |4 aut | |
| 700 | 1 | |a Isasi, Carmen R |e verfasserin |4 aut | |
| 700 | 1 | |a Raffield, Laura M |e verfasserin |4 aut | |
| 700 | 1 | |a Elkind, Mitchell S V |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Virginia J |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega, Victor E |e verfasserin |4 aut | |
| 700 | 1 | |a Woodruff, Prescott |e verfasserin |4 aut | |
| 700 | 1 | |a Cole, Shelley A |e verfasserin |4 aut | |
| 700 | 1 | |a Henderson, Joel M |e verfasserin |4 aut | |
| 700 | 1 | |a Mantis, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Monica M |e verfasserin |4 aut | |
| 700 | 1 | |a Demmer, Ryan T |e verfasserin |4 aut | |
| 700 | 1 | |a Oelsner, Elizabeth C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 15(2024), 1 vom: 19. Feb., Seite 1492 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:19 |g month:02 |g pages:1492 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-024-45468-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 19 |c 02 |h 1492 | ||